New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
08:15 EDTPESIPerma-fix Environmental announces formation of Perma-Fix Medical
Perma-Fix Environmental Services announced it intends to grant an exclusive, restricted field of use license to use its new process, technologies and patents when granted, to produce Technetium-99 for medical applications, to a wholly-owned subsidiary, Perma-Fix Medical Corporation. Additionally, the company has engaged WDM, a European investment bank focused on the microcap and healthcare sectors, to assist Perma-Fix Medical in its plans to raise funds outside the United States. Perma-Fix Medical has now completed initial development of its process to produce Tc-99m for medical diagnostic tests, which the Company anticipates will help solve worldwide shortages of Tc-99m.
News For PESI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
08:32 EDTPESIPerma-fix Environmental awarded $2.7M grant
Subscribe for More Information
January 15, 2015
07:33 EDTPESIPerma-fix unit enters into LOI to form strategic partnership with Digirad
Perma-Fix Environmental Services (PESI) announced that its Polish subsidiary, Perma-Fix Medical, S.A., has entered into a preliminary Letter of Intent to form a strategic partnership and secure investment from Digirad Corporation (DRAD), a national provider of in-office nuclear cardiology imaging services. Under the Agreement, Digirad Corporation will invest $1M into Perma-Fix Medical, which is a publicly traded company listed on the NewConnect market of the Warsaw Stock Exchange. The investment, when completed, would constitute approximately 5.4% of the outstanding common shares of Perma-Fix Medical. When completed, Digirad will have the right to appoint one member to Perma-Fix Medical's Supervisory Board, and a second appointee to either the Supervisory Board or the management team. The investment and agreements with Digirad are subject to numerous conditions, including, but not limited to, entering into definitive supply, stock purchase and other agreements, approval by the Boards of Perma-Fix and Digirad and obtaining required approvals by Polish regulatory authorities as to issuance of the shares to Digirad. In connection with the Agreement, Digirad will assist Perma-Fix Medical in the development of and commercialization of Perma Fix Medical's proprietary process to produce Tc-99m without the use of uranium, as well as provide its expertise in the medical imaging business. Upon commencement of Tc-99m production, Perma-Fix Medical will supply Digirad with Tc-99m at a preferred rate.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use